Identification of late-onset hypogonadism in middle-aged and elderly men
- PMID: 20554979
- DOI: 10.1056/NEJMoa0911101
Identification of late-onset hypogonadism in middle-aged and elderly men
Abstract
Background: The association between aging-related testosterone deficiency and late-onset hypogonadism in men remains a controversial concept. We sought evidence-based criteria for identifying late-onset hypogonadism in the general population on the basis of an association between symptoms and a low testosterone level.
Methods: We surveyed a random population sample of 3369 men between the ages of 40 and 79 years at eight European centers. Using questionnaires, we collected data with regard to the subjects' general, sexual, physical, and psychological health. Levels of total testosterone were measured in morning blood samples by mass spectrometry, and free testosterone levels were calculated with the use of Vermeulen's formula. Data were randomly split into separate training and validation sets for confirmatory analyses.
Results: In the training set, symptoms of poor morning erection, low sexual desire, erectile dysfunction, inability to perform vigorous activity, depression, and fatigue were significantly related to the testosterone level. Increased probabilities of the three sexual symptoms and limited physical vigor were discernible with decreased testosterone levels (ranges, 8.0 to 13.0 nmol per liter [2.3 to 3.7 ng per milliliter] for total testosterone and 160 to 280 pmol per liter [46 to 81 pg per milliliter] for free testosterone). However, only the three sexual symptoms had a syndromic association with decreased testosterone levels. An inverse relationship between an increasing number of sexual symptoms and a decreasing testosterone level was observed. These relationships were independently confirmed in the validation set, in which the strengths of the association between symptoms and low testosterone levels determined the minimum criteria necessary to identify late-onset hypogonadism.
Conclusions: Late-onset hypogonadism can be defined by the presence of at least three sexual symptoms associated with a total testosterone level of less than 11 nmol per liter (3.2 ng per milliliter) and a free testosterone level of less than 220 pmol per liter (64 pg per milliliter).
2010 Massachusetts Medical Society
Comment in
-
Testosterone deficiency and replacement in older men.N Engl J Med. 2010 Jul 8;363(2):189-91. doi: 10.1056/NEJMe1006197. N Engl J Med. 2010. PMID: 20647215 No abstract available.
-
Late-onset hypogonadism in middle-aged and elderly men.N Engl J Med. 2010 Nov 4;363(19):1868; author reply 1868-9. doi: 10.1056/NEJMc1009328. N Engl J Med. 2010. PMID: 21047238 No abstract available.
-
Late-onset hypogonadism in middle-aged and elderly men.N Engl J Med. 2010 Nov 4;363(19):1867-8; author reply 1868-9. doi: 10.1056/NEJMc1009328. N Engl J Med. 2010. PMID: 21047239 No abstract available.
-
Words of Wisdom. Re: identification of late-onset hypogonadism in middle-aged and elderly men.Eur Urol. 2011 Jan;59(1):168. doi: 10.1016/j.eururo.2010.10.011. Eur Urol. 2011. PMID: 21414870 No abstract available.
Similar articles
-
Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects.J Endocrinol Invest. 2005;28(3 Suppl):23-7. J Endocrinol Invest. 2005. PMID: 16042356
-
Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction.Aging Male. 2002 Mar;5(1):38-46. Aging Male. 2002. PMID: 12040974
-
Late-onset hypogonadism.Med Clin North Am. 2011 May;95(3):507-23, x. doi: 10.1016/j.mcna.2011.03.001. Med Clin North Am. 2011. PMID: 21549875 Review.
-
Hypogonadism is associated with overt depression symptoms in men with erectile dysfunction.Int J Impot Res. 2008 Mar-Apr;20(2):157-61. doi: 10.1038/sj.ijir.3901576. Epub 2007 Aug 16. Int J Impot Res. 2008. PMID: 17703222
-
Testosterone and erectile physiology.Aging Male. 2006 Dec;9(4):201-6. doi: 10.1080/13685530601051155. Aging Male. 2006. PMID: 17178555 Review.
Cited by
-
Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010.Public Health Rep. 2015 Mar-Apr;130(2):143-52. doi: 10.1177/003335491513000207. Public Health Rep. 2015. PMID: 25729103 Free PMC article.
-
Drug ligand-induced activation of translocator protein (TSPO) stimulates steroid production by aged brown Norway rat Leydig cells.Endocrinology. 2013 Jun;154(6):2156-65. doi: 10.1210/en.2012-2226. Epub 2013 Mar 22. Endocrinology. 2013. PMID: 23525219 Free PMC article.
-
Changes in white adipose tissue gene expression in a randomized control trial of dieting obese men with lowered serum testosterone alone or in combination with testosterone treatment.Endocrine. 2021 Aug;73(2):463-471. doi: 10.1007/s12020-021-02722-0. Epub 2021 Apr 17. Endocrine. 2021. PMID: 33864607 Clinical Trial.
-
Long-term administration of resveratrol and MitoQ stimulates cavernosum antioxidant gene expression in a mouse castration model of erectile dysfunction.Life Sci. 2022 Dec 1;310:121082. doi: 10.1016/j.lfs.2022.121082. Epub 2022 Oct 15. Life Sci. 2022. PMID: 36252696 Free PMC article.
-
Low Testosterone in Men with Cardiovascular Disease or Risk Factors: To Treat or Not To Treat?Curr Treat Options Cardiovasc Med. 2016 Dec;18(12):75. doi: 10.1007/s11936-016-0496-0. Curr Treat Options Cardiovasc Med. 2016. PMID: 27807794 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical